BioSpace News Archive

Quest Diagnostics, the leader in diagnostic information services, announced the launch of its first consumer-initiated genetic test, now exclusively available through the company’s consumer health business at questhealth.com.

BrainsWay Ltd. today announced the expanded market penetration of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in India.

Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has dosed the first participant in the Phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).

SYBLEU INC. is preparing to begin advancing small molecule drug therapies for animal and human health.

Soligenix, Inc. announced today the expansion of its Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis after demonstration of biological effect in the initial five subjects.

Capsida Biotherapeutics (“Capsida”) today announced research published in Nature Nanotechnology describing an adeno-associated virus (AAV) variant that can more effectively transduce the brain in non-human primates (NHPs) than AAV9.

TeleMED Diagnostic Management Inc. has announced its tenth deployment of its new ViTELflo module for reviewing and reporting Echocardiography and Stress Echocardiography studies.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it has been selected to present the Company’s scientific advancement of its key asset MB-204 titled MB-204:

Ocean Biomedical, Inc. announced that it is focusing its multi-pronged malaria program to address the chronic malaria crisis in sub-Saharan Africa while recognizing newly emerging global malaria challenges.

Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the first participants have been dosed in a Phase 1 healthy volunteer study of HIB210, an investigational monoclonal antibody targeting C5aR1.